5-Bromo-3-Methyl-1,2-Thiazole

For pharmaceutical programs targeting ATP-competitive kinase inhibition, 5-bromo-3-methylisothiazole serves as a privileged electrophilic partner in sp²–sp² cross-coupling manifolds, where the C5 bromine atom undergoes oxidative addition to Pd(0) with activation energies sufficiently low to permit catalytic turnover at ambient pressure. Industrial batch records from kilo-lab campaigns indicate that a catalyst system comprising Pd(PPh₃)₄ at 1.5–2.0 mol% loading, in the presence of 2.0 M aqueous K₂CO₃ and a deoxygenated 1,4-dioxane/water mixture (4:1 v/v), delivers consistent isolated yields of 78–92% when reacted with arylboronic acids bearing electron-withdrawing substituents. The stoichiometric ratio of boronic acid to bromide is typically held at 1.15:1 to compensate for protodeboronation losses; exceeding 1.3:1 leads to Pd black precipitation and reactor wall fouling in un-baffled glass-lined vessels. Process safety reviews mandate strict oxygen exclusion below 50 ppm dissolved O₂ to suppress homocoupling by-products, verified by inline optical fluorescence quenching probes calibrated to ISO 5813:2014 methodology. The resulting 5-aryl-3-methylisothiazole intermediates are elaborated into clinical candidates exemplified by a series of dual JAK2/FLT3 inhibitors where the isothiazole ring mimics the hinge-binding motif of adenine, with co-crystal structures confirming the methyl group at C3 occupies a lipophilic pocket lined by Val911 and Leu983. Residual palladium is scavenged to <10 ppm via treatment with trimercaptotriazine-functionalised silica at 60°C for 4 h, meeting the ICH Q3D oral permitted daily exposure limit for elemental impurities. Pharmacopoeial compliance of the final active pharmaceutical ingredient requires the brominated precursor to exhibit ≥99.5% purity by area-normalised HPLC at 254 nm and a single impurity not exceeding 0.15%, as specified under a custom drug master file monograph aligned with Ph. Eur. 2.2.46 chromatographic separation parameters.

Agrochemical Access to 3-Methylisothiazole-Bearing Succinate Dehydrogenase Inhibitors

Synthetic elaboration of 5-bromo-3-methylisothiazole into the acid chloride or N-methoxy amide pharmacophore via sequential magnesium-halogen exchange and quench with carbon dioxide proceeds with an exotherm that, on scale beyond 50 L reactor volume, demands jacket temperature ramp rates no faster than 2°C/min to avoid runaway Grignard initiation. Pilot plant data from a contract manufacturing organisation confirms that the organomagnesium intermediate, formed by treating the bromide with i-PrMgCl·LiCl in THF at −20°C, must be held at −15 ± 3°C for 45 min to ensure complete halogen-metal exchange before introduction of CO₂ gas through a subsurface dip tube at 0.3 bar gauge pressure. The crude 3-methylisothiazole-5-carboxylic acid is subsequently coupled to an amine intermediate using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole in dichloromethane, with a molar ratio of 1:1.05:1.3 for acid : EDC : HOBt; any deviation beyond 1.2 equivalents of HOBt significantly retards filtration because of gelatinous urea by-product accumulation in the 0.5 µm inline filter housing. The final technical-grade fungicide is formulated as a 250 g/L SC (suspension concentrate) according to CIPAC MT 184 wet sieve test methodology, with particle size distribution D₉₀ controlled below 4 µm via wet bead milling using 0.6–0.8 mm yttria-stabilised zirconia media. Field trial data generated in compliance with OECD Test Guideline 509 demonstrate that the isothiazole-containing SDHI achieves ≥85% control of Septoria tritici at 100 g a.i./ha under high disease pressure in Northern European winter wheat, positioning it as a resistance-breaking alternative to fluxapyroxad. REACH registration dossier sections 3 and 9 require the report of vapour pressure (<2.0 × 10⁻⁵ Pa at 25°C, measured by OECD TG 104 effusion method) and octanol-water partition coefficient (log Kow 1.8 ± 0.2, OECD TG 107 shake-flask) for this class of intermediate, which remains classified under UN number 3077 (environmentally hazardous substance) during sea freight due to chronic aquatic toxicity category 3 in mixtures containing >0.1% free isothiazole.

Electrochemical deposition of poly(isothiazole) films onto ITO-coated glass requires a monomer with a leaving group at the 5-position to ensure uninterrupted 2,5-coupling propagation; 5-bromo-3-methylisothiazole fulfils this requirement by undergoing reductive debromination at a peak potential of −1.12 V vs. Ag/AgCl in acetonitrile containing 0.1 M tetrabutylammonium hexafluorophosphate, as determined by cyclic voltammetry under nitrogen blanket. The polymerisation bath is maintained at 0°C to suppress competing nucleophilic attack by residual water, and monomer concentration is adjusted to 50 mM within a jacketed three-electrode cell equipped with a Pt gauze auxiliary electrode. Repeated potential cycling between −1.3 V and +1.6 V at a scan rate of 50 mV/s yields an adherent film whose optical density at 450 nm grows linearly up to 40 cycles, beyond which the film becomes mechanically brittle and exhibits surface cracking under SEM inspection at 5,000× magnification due to internal stress accumulation exceeding 8 MPa. Electrical conductivity of the dedoped film, measured by the four-point probe method in accordance with ASTM F84-93, falls within 1.2–2.8 S/cm after vapour-phase doping with iodine at 10⁻² mbar for 6 h, values comparable to polythiophene analogues. The electropolymerised layer finds utility as a hole-transport interlayer in perovskite photovoltaic devices, where a thickness of 25 ± 5 nm spin-coated from a chlorobenzene solution onto PEDOT:PSS is shown to reduce series resistance by 18% without compromising fill factor, provided that the isothiazole monomer is rigorously purified by vacuum sublimation at 55°C and 0.02 mbar to remove residual coupling-competent impurities. Device fabrication protocols developed at several pilot-line facilities adopt this material in combination with MA_0.85FA_0.15PbI₃ absorbers, and long-term stability testing under IEC 61215-1:2021 damp-heat conditions (85°C, 85% RH, 1,000 h) reveals <5% degradation in power conversion efficiency when encapsulated with a transparent barrier adhesive from a commercial tier-1 supplier.

When This Brominated Scaffold Replaces 2-Bromothiazole in Fragment-Based Library Construction

Parallel synthesis campaigns that generate diverse heterobiaryl collections often rely on the differential reactivity of dihalogenated precursors, and 5-bromo-3-methylisothiazole provides a monofunctionalised core with predictable orthogonal site selectivity. Automated platform records from a Tecan Freedom EVO® liquid handler, configured with 96-well glass microreactors sealed under argon, document that Pd-catalysed amination using BrettPhos Pd G3 at 1 mol% and LiHMDS base (2.5 equiv.) in THF at 55°C achieves ≥80% consumption of the bromide within 2 h when amines are delivered in 1.2-fold molar excess. The resulting C5-aminated isothiazole fragments are purified by catch-and-release solid-phase extraction on SCX-2 cartridges to a purity threshold of 95% as verified by LCMS using an evaporative light-scattering detector calibrated against external standards certified to ISO 17034. Each member of the fragment library is stored as a 50 mM DMSO-d₆ solution in Matrix barcoded microtubes under argon-blanketed headspace, with freeze-thaw lability assessed by ¹H NMR integration every 10 cycles to flag any compound showing >2% decomposition. Thermodynamic solubility in pH 7.4 phosphate-buffered saline, measured by the chiral capillary electrophoresis method derived from Ph. Eur. 2.2.31, routinely exceeds 180 µM for the N-arylpiperazine adducts, rendering them suitable for fragment-based screening against GPCR targets at screening concentrations of 200 µM without excipient interference. The REACH compliance requirements for such R&D libraries are handled under the 68 L/a exemption threshold for substances used in scientific research, with the legal entity maintaining an internal exposure scenario documented per ECHA R.15 guidance; nevertheless, outgoing shipments to non-EU collaborative sites are accompanied by a safety data sheet that reports the bromide as causing serious eye irritation (Category 2, H319) based on in vitro corneal opacity tests conducted with OECD TG 437.

Corrosion Inhibitor Formulation: Synergy with Zinc Phosphate in Epoxy-Polyamide Primers

When 5-bromo-3-methylisothiazole is converted to its 5-mercapto derivative via thiourea-mediated thiolation in refluxing ethanol (molar ratio thiourea:bromide 1.05:1, reaction time 6 h) and subsequently incorporated into an epoxy-polyamide primer, the resulting coating exhibits a mixed anodic-cathodic inhibition mechanism that becomes measurable at addition levels as low as 0.8 wt% on total resin solids. Electrochemical impedance spectroscopy carried out on mild steel coupons in 3.5 wt% NaCl electrolyte in accordance with ASTM G106-89 standard practice reveals that the charge-transfer resistance (R_ct) increases from 1.2 kΩ·cm² for the unmodified primer to 14.5 kΩ·cm² after 168 h immersion when the isothiazole synergist is combined with zinc phosphate in a 1:3 w/w ratio. The formulation's pot life, assessed by recording viscosity build-up to 100 KU on a Stormer viscometer at 25°C, extends by 45 min when the organic inhibitor is present, attributable to chelation of the cobalt drier residues by the thiolate form and confirmed by UV-Vis bathochromic shift from 580 nm to 602 nm. Salt spray exposure under ASTM B117-19 for 1,000 h produces scribe creep widths of 1.8 mm for the isothiazole-containing system versus 3.5 mm for the zinc-phosphate-only control, provided that the pre-dispersion step uses a zirconium bead mill with 0.3 mm media to achieve a Hegman grind of 6.5 NS and the inhibitor is pre-neutralised to pH 7.0 ± 0.2 with triethylamine before letdown. Long-term storage stability over 12 months at 40°C in sealed containers exhibits no phase separation or gelling as long as the epoxy resin EEW is maintained within 450–500 g/eq and the polyamide hardener amine value does not exceed 230 mg KOH/g. Industrial tank lining specifications that reference ISO 12944-6:2018 C5-I high-durability environments have adopted such formulations after qualification testing on 3,000 L storage tanks containing desalted crude, where pitting density was reduced by 62% compared with the preceding zinc-phosphate benchmark over a 24-month inspection interval.

In Situ Generation of 3-Hydroxyisothiazole Biocides Through Controlled Hydrolysis

Aqueous hydrolysis of 5-bromo-3-methylisothiazole at 80°C under mildly acidic conditions (0.1 M H₂SO₄, 6 h) generates 3-methylisothiazol-3-one, which tautomerises to the active biocide MIT, with the reaction being tracked by iodine titration of the eliminated bromide to confirm conversion exceeding 97%. The crude hydrolysate, after neutralisation with NaOH to pH 6.0 and addition of 0.5 wt% of a proprietary copper stabiliser chelating agent, is formulated into a 14% active aqueous solution and dosed at 15–25 ppm in metalworking fluid central systems to control bacterial counts below 10⁴ CFU/mL as per ASTM E2275-19 dip-slide method. The biocide product is registered under the EU Biocidal Products Regulation (EU) No 528/2012 for product-type PT 13 (metalworking preservatives), and the technical equivalence of the active substance is demonstrated through a five-batch analysis report showing consistency in relative density (1.023–1.028 g/mL at 25°C, ISO 12185:2024) and active content variability ≤1.5%. The stability of the formulated product passes accelerated storage at 54°C for 14 days with less than 3% active loss as monitored by reverse-phase HPLC using a C18 column and 210 nm detection. Because trace amounts of residual 5-bromo-3-methylisothiazole may persist at <20 ppm, the toxicological profile of the formulation must consider the brominated precursor's eye irritation potential, and the label accordingly carries the precautionary statement P305+P351+P338 in accordance with Regulation (EC) No 1272/2008 Annex II.